ReviewCancer immunology, immunotherapy : CII2015
Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer.
Review in Cancer immunology, immunotherapy : CII, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- The use of RNA-based treatments in the field of cancer immunotherapy.Molecular cancer · 2023Review
- IEDB and CEDAR: Two Sibling Databases to Serve the Global Scientific Community.Methods in molecular biology (Clifton, N.J.) · 2023Article
- SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.Journal for immunotherapy of cancer · 2020Article
- Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma.BMC immunology · 2019Article
- The role of cancer stem cells in the modulation of anti-tumor immune responses.Seminars in cancer biology · 2018Review
- Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges.Biomedicines · 2018Review
- Methods for improving the immunogenicity and efficacy of cancer vaccines.Expert opinion on biological therapy · 2018Review
- Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.Oncotarget · 2017Review
- HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.Oncotarget · 2017Article
- Emerging role of mutations in epigenetic regulators including MLL2 derived from The Cancer Genome Atlas for cervical cancer.BMC cancer · 2017Article
- Whole-exome sequencing predicted cancer epitope trees of 23 early cervical cancers in Chinese women.Cancer medicine · 2017Article
- Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets.Human vaccines & immunotherapeutics · 2016Review
- Melanoma Cancer Stem Cells: Markers and Functions.Cancers · 2016Review
- pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens.Genome medicine · 2016Article
- Analogue peptides for the immunotherapy of human acute myeloid leukemia.Cancer immunology, immunotherapy : CII · 2015Review
- Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy.Vaccines · 2015Review
- Trial watch: Naked and vectored DNA-based anticancer vaccines.Oncoimmunology · 2015Article
- Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination.OncoimmunologyArticle
- Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although cancer immunotherapy shows efficacy with adoptive T cell therapy (ACT) and antibody-based immune checkpoint blockade, efficacious therapeutic vaccination of cancer patients with tumor-associated antigens (TAAs) remains largely unmet. Current cancer vaccines utilize nonmutated shared TAAs that may have suboptimal immunogenicity. Experimental evidence underscores the strong immunogenicity of unique TAAs derived from somatically mutated cancer proteins, whose massive characterization has been precluded until recently by technical limitations. The development of cost-effective, high-throughput DNA sequencing approaches makes now possible the rapid identification of all the somatic mutations contained in a cancer cell genome. This method, combined with robust bioinformatics platforms for T cell epitope prediction and established reverse immunology approaches, provides us with an integrated strategy to identify patient-specific unique TAAs in a relatively short time, compatible with their potential use in the clinic. Hence, it is now for the first time possible to quantitatively define the patient's unique tumor antigenome and exploit it for vaccination, possibly in combination with ACT and/or immune checkpoint blockade to further increase immunotherapy efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.